{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:18:03Z","timestamp":1773479883347,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015283","name":"Bloomberg Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.josat.2024.209545","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:58:54Z","timestamp":1729526334000},"page":"209545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data"],"prefix":"10.1016","volume":"168","author":[{"given":"Kenneth A.","family":"Feder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn N.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isha K.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209545_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13012-014-0192-y","article-title":"Leadership and organizational change for implementation (LOCI): A randomized mixed method pilot study of a leadership and organization development intervention for evidence-based practice implementation","volume":"10","author":"Aarons","year":"2015","journal-title":"Implementation Science: IS"},{"key":"10.1016\/j.josat.2024.209545_bb0010","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"Journal of Statistical Software"},{"key":"10.1016\/j.josat.2024.209545_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/08964289.2019.1588220","article-title":"Ubiquitous yet unclear: A systematic review of medical mistrust","author":"Benkert","year":"2019","journal-title":"Behavioral Medicine"},{"key":"10.1016\/j.josat.2024.209545_bb0020","article-title":"Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership","volume":"209351","author":"Burke","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"issue":"5","key":"10.1016\/j.josat.2024.209545_bb0025","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3122\/jabfm.2019.05.190012","article-title":"Predictors of medication-assisted treatment initiation for opioid use disorder in an interdisciplinary primary care model","volume":"32","author":"Cantone","year":"2019","journal-title":"The Journal of the American Board of Family Medicine"},{"key":"10.1016\/j.josat.2024.209545_bb0030","author":"Centers for Disease Control and Prevention, National Center for Health Statistics"},{"issue":"3","key":"10.1016\/j.josat.2024.209545_bb0035","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.josat.2024.209545_bb0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jsat.2006.06.016","article-title":"The role of organization and management in substance abuse treatment: Review and roadmap","volume":"31","author":"D\u2019Aunno","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2024.209545_bb0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/08897077.2019.1572052","article-title":"Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?","volume":"40","author":"Doernberg","year":"2019","journal-title":"Substance Abuse"},{"issue":"6","key":"10.1016\/j.josat.2024.209545_bb0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder","volume":"60","author":"Feder","year":"2017","journal-title":"Journal of Adolescent Health"},{"issue":"6","key":"10.1016\/j.josat.2024.209545_bb0055","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15288\/jsad.2018.79.909","article-title":"Barriers and facilitators to implementation of pharmacotherapy for opioid use disorders in VHA residential treatment programs","volume":"79","author":"Finlay","year":"2018","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"12","key":"10.1016\/j.josat.2024.209545_bb0060","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1007\/s11606-022-07405-8","article-title":"Lack of racial and ethnic diversity among addiction physicians","volume":"37","author":"Garcia","year":"2022","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2024.209545_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103715","article-title":"A mixed methods study of provider factors in buprenorphine treatment retention","volume":"105","author":"Gertner","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"4","key":"10.1016\/j.josat.2024.209545_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1207\/S15328031US0104_02","article-title":"Partitioning variation in multilevel models","volume":"1","author":"Goldstein","year":"2002","journal-title":"Understanding Statistics"},{"key":"10.1016\/j.josat.2024.209545_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102768","article-title":"A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system","volume":"81","author":"Grella","year":"2020","journal-title":"International Journal of Drug Policy"},{"issue":"8","key":"10.1016\/j.josat.2024.209545_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001\u20132014","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatrics"},{"issue":"1","key":"10.1016\/j.josat.2024.209545_bb0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13722-018-0127-z","article-title":"Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): Protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities","volume":"13","author":"Hagedorn","year":"2018","journal-title":"Addiction Science & Clinical Practice"},{"issue":"14","key":"10.1016\/j.josat.2024.209545_bb0090","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1007\/s11606-021-07274-7","article-title":"Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): An implementation trial in eight veterans health administration facilities","volume":"37","author":"Hagedorn","year":"2022","journal-title":"Journal of General Internal Medicine"},{"issue":"3","key":"10.1016\/j.josat.2024.209545_bb0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in new York City","volume":"40","author":"Hansen","year":"2013","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.josat.2024.209545_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren\u2019t physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2024.209545_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20843","article-title":"Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States","volume":"3","author":"Huhn","year":"2020","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2024.209545_bb0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11414-020-09706-4","article-title":"Organizational facilitators and barriers to medication for opioid use disorder capacity expansion and use","volume":"47","author":"Jacobson","year":"2020","journal-title":"The Journal of Behavioral Health Services & Research"},{"issue":"4","key":"10.1016\/j.josat.2024.209545_bb0115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.evalprogplan.2011.02.004","article-title":"Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure","volume":"34","author":"Knudsen","year":"2011","journal-title":"Evaluation and Program Planning"},{"issue":"1","key":"10.1016\/j.josat.2024.209545_bb0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13722-022-00313-6","article-title":"Jail-based treatment for opioid use disorder in the era of bail reform: A qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative","volume":"17","author":"Krawczyk","year":"2022","journal-title":"Addiction Science & Clinical Practice"},{"issue":"9","key":"10.1016\/j.josat.2024.209545_bb0125","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/add.14991","article-title":"Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services","volume":"115","author":"Krawczyk","year":"2020","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.josat.2024.209545_bb0130","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2024.209545_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"9","key":"10.1016\/j.josat.2024.209545_bb0140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209545_bb0145","series-title":"Multilevel modelling for public health and health services research: Health in context [internet]","article-title":"Context, composition and how their influences vary","author":"Leyland","year":"2020"},{"issue":"5","key":"10.1016\/j.josat.2024.209545_bb0150","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpain.2014.01.488","article-title":"Racial Bias in pain perception and response: Experimental examination of automatic and deliberate processes","volume":"15","author":"Mathur","year":"2014","journal-title":"The Journal of Pain"},{"issue":"3","key":"10.1016\/j.josat.2024.209545_bb0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209545_bb0160","series-title":"Characteristics of individuals who receive pharmacotherapy while in treatment for opioid use disorder in the United States","author":"Mutter","year":"2019"},{"key":"10.1016\/j.josat.2024.209545_bb0165","author":"Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder"},{"key":"10.1016\/j.josat.2024.209545_bb0170","author":"R Core Team"},{"issue":"10","key":"10.1016\/j.josat.2024.209545_bb0175","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2105\/AJPH.2023.307388","article-title":"Time to end racial disparities in buprenorphine access","volume":"113","author":"Rosen","year":"2023","journal-title":"American Journal of Public Health"},{"issue":"8","key":"10.1016\/j.josat.2024.209545_bb0180","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamapediatrics.2017.1269","article-title":"Closing the medication-assisted treatment gap for youth with opioid use disorder","volume":"171","author":"Saloner","year":"2017","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.josat.2024.209545_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108900","article-title":"Not in my treatment center: Leadership\u2019s perception of barriers to MOUD adoption","volume":"144","author":"Stewart","year":"2023","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209545_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108176","article-title":"It\u2019s not just the money: The role of treatment ideology in publicly funded substance use disorder treatment","volume":"120","author":"Stewart","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209545_bb0195","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.josat.2024.209545_bb0200","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). (n.d.). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report."},{"issue":"2","key":"10.1016\/j.josat.2024.209545_bb0205","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1037\/a0035204","article-title":"Racial\/ethnic disparities in the assessment and treatment of pain: Psychosocial perspectives","volume":"69","author":"Tait","year":"2014","journal-title":"American Psychologist"},{"issue":"5","key":"10.1016\/j.josat.2024.209545_bb0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.12030","article-title":"Buprenorphine utilization and prescribing among New Jersey Medicaid beneficiaries after adoption of initiatives designed to improve treatment access","volume":"6","author":"Treitler","year":"2023","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209545_bb0215","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/08897077.2022.2060448","article-title":"Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons","volume":"43","author":"Treitler","year":"2022","journal-title":"Substance Abuse"},{"issue":"22","key":"10.1016\/j.josat.2024.209545_bb0220","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014Tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.josat.2024.209545_bb0225","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2024.209545_bb0230","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/aje\/kws412","article-title":"The table 2 fallacy: Presenting and interpreting confounder and modifier coefficients","volume":"177","author":"Westreich","year":"2013","journal-title":"American Journal of Epidemiology"},{"issue":"10","key":"10.1016\/j.josat.2024.209545_bb0235","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/10810730.2019.1669742","article-title":"Does discrimination breed mistrust? Examining the role of mediated and non-mediated discrimination experiences in medical mistrust","volume":"24","author":"Williamson","year":"2019","journal-title":"Journal of Health Communication"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T06:19:10Z","timestamp":1733293150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924002571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":47,"alternative-id":["S2949875924002571"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209545","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209545"}}